Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Aflibercept for Choroidal Neovascularization Secondary to Angioid Streaks (EYLEA-STRIE)
2014-000986-30Phase 2Completed
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- May 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aflibercept in Subretinal neovascularization, sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Mean average change in BCVA from baseline to month 12. Started May 2014; status: completed.
02
Drugs
aflibercept
03
Conditions
Subretinal neovascularization
Beyond the preview
Go deeper on 2014-000986-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000986-30.